Eli Lilly launches cheaper vial version of blockbuster weight-loss drug Date Tuesday, August 27, 2024 - 9:01 AM Description US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound
Eli Lilly lifts guidance on strong sales of diabetes and weight loss drugs Date Tuesday, April 30, 2024 - 10:45 AM Description Shares of world’s most valuable pharmaceuticals group reapproach record highs
Eli Lilly predicts sales jump from obesity drug demand Image Date Tuesday, February 06, 2024 - 6:28 AM Description Drugmaker forecasts higher than expected annual revenue due to soaring demand for weight-loss medication
Eli Lilly races to boost capacity for rival to Novo Nordisk weight-loss drug Image Date Monday, March 04, 2024 - 10:00 PM Description US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
Eli Lilly raises outlook on bumper sales of diabetes and weight loss drugs Date Thursday, August 08, 2024 - 7:54 AM Description Shares soar as ‘strong performance’ of Mounjaro and Zepbound medicines underpin jump in revenue
Eli Lilly rides the weight-loss drug boom Date Tuesday, October 01, 2024 - 10:00 PM Description The company is set to become the first $1tn drugmaker, but investors see warning signs it has reached ‘peak enthusiasm’
Eli Lilly says diabetes and obesity drugs will boost sales by 20% this year Image Date Monday, February 05, 2024 - 11:02 PM
Eli Lilly shares fall after revenue miss for blockbuster weight-loss drugs Date Tuesday, January 14, 2025 - 9:02 AM Description Sales figures for Mounjaro and Zepbound spook investors in world’s biggest drugmaker
Eli Lilly shares surge after study shows weight-loss drug cuts diabetes risk Date Tuesday, August 20, 2024 - 10:24 AM
Eli Lilly to buy cancer specialist Point for $1.4bn Date Tuesday, October 03, 2023 - 10:08 AM Description Point is developing radioligand molecules that can deliver targeted radiation to tumour cells